Background: Pancreatic cancer (PC) is one of the deadliest cancers worldwide for which little clinical progress has been made in the last decades. Furthermore, increased trends of PC mortality rates have been reported in Westernised countries. PC is usually diagnosed in advanced stages, precluding patients of an effective treatment. Identifying high-risk populations and early detection markers is the first and crucial step to impact on these figures and change the PC horizon. Aims/Objectives: To discuss the published body of evidence on host and tumor genomics promising markers for primary and/or secondary personalised PC prevention, as well as the future perspectives in the field. Methods: A review of the literature was performed to identify germline and tumor DNA and RNA markers that showed potential usefulness in defining the high-risk population, diagnosing the disease early, and identifying new carcinogens associated with PC. Results: Only high-penetrance inherited mutations are used, at present, to define the high-risk PC population. Although there are some promising genomics markers to be used as early detection tests, none has been validated adequately to be integrated into the clinics routine. Conclusions: Despite of important efforts made in the recent time, little progress has been made to better characterise high-risk PC populations and to identify genomics-based markers for its early diagnosis. PC rates continue to rise, and this disease is becoming a real public health problem in the Westernised world. International and multidisciplinary strategies to identify new markers and properly validate the promising ones are urgently needed to implement cost-efficient primary and secondary prevention interventions in PC.

Journal Section:
Editor's choice
Keywords:
Genomics, Pancreatic cancer, DNA mutations, DNA methylation, RNA expression, Genetic variants, Primary prevention, Secondary prevention, Screening, Risk prediction score
1.
World Health Organization: Global Health Observatory Data. NCD Mortality and Morbidity. Geneva, World Health Organization, 2017.
2.
Cancer Research UK: Statistics on Preventable Cancers. www.cancerresearchuk.org/health-professional/cancer-statistics/risk/preventable-cancers.
3.
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
4.
Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E: European cancer mortality predictions for the year 2014. Ann Oncol 2014;25:1650-1656.
5.
Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, Negri E: European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol 2015;26:779-786.
6.
Lucas AL, Malvezzi M, Carioli G, Negri E, La Vecchia C, Boffetta P, Bosetti C: Global trends in pancreatic cancer mortality from 1980 through 2013 and predictions for 2017. Clin Gastroenterol Hepatol 2016;14:1452-1462.
7.
Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E: European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol DOI: 10.1093/annonc/mdx033.
8.
Ferlay J, Partensky C, Bray F: More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol 2016;55:1158-1160.
9.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM: Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-2921.
10.
Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP: Pancreatic cancer. Nat Rev Dis Primers 2016;2:16022.
11.
Amundadottir LT: Pancreatic cancer genetics. Int J Biol Sci 2016;12:314-325.
12.
Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, Bonsing BA, de Vos Tot Nederveen Cappel WH, Bergman W, Wasser M, Morreau H, Klöppel G, Schicker C, Steinkamp M, Figiel J, Esposito I, Mocci E, Vazquez-Sequeiros E, Sanjuanbenito A, Muñoz-Beltran M, Montans J, Langer P, Fendrich V, Bartsch DK: Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol 2016;34:2010-2019.
13.
GWAS Catalog: The NHGRI-EBI Catalog of published genome-wide association studies. https://www.ebi.ac.uk/gwas/.
14.
MacDonald RJ, Swift GH, Real FX: Transcriptional control of acinar development and homeostasis. Prog Mol Biol Transl Sci 2010;97:1-40.
15.
Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP: PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007;25:1417-1422.
16.
Zhao D, Weng C: Combining PubMed knowledge and EHR data to develop a weighted bayesian network for pancreatic cancer prediction. J Biomed Inform 2011;44:859-868.
17.
Pierce BL, Tong L, Kraft P, Ahsan H: Unidentified genetic variants influence pancreatic cancer risk: an analysis of polygenic susceptibility in the PanScan study. Genet Epidemiol 2012;36:517-524.
18.
Hippisley-Cox J, Coupland C: Identifying patients with suspected pancreatic cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2012;62:e38-e45.
19.
Klein AP, Lindström S, Mendelsohn JB, Steplowski E, Arslan AA, et al: An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One 2013;8:e72311.
20.
Risch HA, Yu H, Lu L, Kidd MS: Detectable symptomatology preceding the diagnosis of pancreatic cancer and absolute risk of pancreatic cancer diagnosis. Am J Epidemiol 2015;182:26-34.
21.
Yu A, Woo SM, Joo J, Yang HR, Lee WJ, Park SJ, Nam BH: Development and validation of a prediction model to estimate individual risk of pancreatic cancer. PLoS One 2016;11: e0146473.
22.
Feil R, Fraga MF: Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet 2012;13:97-109.
23.
Ong TP, Moreno FS, Ross SA: Targeting the epigenome with bioactive food components for cancer prevention. J Nutrigenet Nutrigenomics 2011;4:275-292.
24.
Baylin SB, Jones PA: A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011;11:726-734.
25.
Pedersen KS, Bamlet WR, Oberg AL, de Andrade M, Matsumoto ME, Tang H, Thibodeau SN, Petersen GM, Wang L: Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS One 2011;6:e18223.
26.
Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806.
27.
Dreyer SB, Chang DK, Bailey P, Biankin AV: Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clin Cancer Res 2017;23:1638-1646.
28.
Brennan P, Wild CP: Genomics of cancer and a new era for cancer prevention. PLoS Genet 2015;11:e1005522.
29.
Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, Totoki Y, Fujimoto A, Nakagawa H, Shibata T, Campbell PJ, Vineis P, Phillips DH, Stratton MR: Mutational signatures associated with tobacco smoking in human cancer. Science 2016;354:618-622.
30.
Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA; Cancer Genome Atlas Research Network, Benz CC, Perou CM, Stuart JM: Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014;158:929-944.
31.
Bailey P, Chang DK, Nones K, Johns AL, Patch AM, et al: Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531:47-52.
32.
Han X, Wang J, Sun Y: Circulating tumor DNA as biomarkers for cancer detection. Genomics Proteomics Bioinformatics 2017;15:59-72.
33.
Takai E, Yachida S: Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer. World J Gastroenterol 2016;22:8480-8488.
34.
Mao Y, Shen J, Lu Y, Lin K, Wang H, Li Y, Chang P, Walker MG, Li D: RNA sequencing analyses reveal novel differentially expressed genes and pathways in pancreatic cancer. Oncotarget 2017;8:42537-42547.
35.
Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW: Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17:500-503.
36.
Huang J, Liu J, Chen-Xiao K, Zhang X, Lee WN, Go VL, Xiao GG: Advance in microRNA as a potential biomarker for early detection of pancreatic cancer. Biomark Res 2016;4:20.
37.
Previdi MC, Carotenuto P, Zito D, Pandolfo R, Braconi C: Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know? Future Oncol 2017;13:443-453.
38.
Kisiel JB, Raimondo M, Taylor WR, Yab TC, Mahoney DW, Sun Z, Middha S, Baheti S, Zou H, Smyrk TC, Boardman LA, Petersen GM, Ahlquist DA: New DNA methylation markers for pancreatic cancer: discovery, tissue validation, and pilot testing in pancreatic juice. Clin Cancer Res 2015;21:4473-4481.
39.
Bitton A, Gaziano TA: The Framingham Heart Study's impact on global risk assessment. Prog Cardiovasc Dis 2010;53:68-78.
40.
Gomez-Rubio P, Zock JP, Rava M, Marquez M, Sharp L, Hidalgo M, Carrato A, Ilzarbe L, Michalski C, Molero X, Farré A, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberà V, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Alvarez-Urturi C, Balcells J, Barneo L, Costello E, Guillén-Ponce C, Kleeff J, Kong B, Lawlor R, Löhr M, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Scarpa A, Real FX, Malats N; PanGenEU Study Investigators: Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut 2017;66:314-322.
41.
Gomez-Rubio P, Rosato V, Marquez M, Bosetti C, Molina-Montes E, Rava M, Piñero J, Michalski CW, Farré A, Molero X, Löhr M, Ilzarbe L, Perea J, Greenhalf W,O'Rorke M, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Gutiérrez-Sacristán A, Balsells J, Costello E, Guillén-Ponce C, Huang J, Iglesias M, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Lawlor RT, Carrato A, Hidalgo M, Scarpa A, Sharp L, Furlong LI, Real FX, La Vecchia C, Malats N; PanGenEU Study Investigators: A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. Ann Oncol DOI: 10.1093/annonc/mdx167.
42.
López de Maturana E, Pineda S, Brand A, Van Steen K, Malats N: Toward the integration of Omics data in epidemiological studies: still a “long and winding road.” Genet Epidemiol 2016;40:558-569.
43.
US Congress: The Recalcitrant Cancer Research Act of 2012 (Public Law 112-239, §1083). Pancreatic Cancer Research and Education Act involving research for biomarkers of early detection. Washington, US Government Printing Office, 2014.
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.